Urothelial bladder carcinoma (UBC) is an intricate malignancy with a variable natural history and clinical behavior. Despite developments in diagnosis/prognosis refi nement and treatment modalities, the recurrence rate is high, and progression from non-muscle to muscle invasive UBC commonly leads to metastasis. Moreover, patients with muscle-invasive or extra-vesical disease often fail the standard chemotherapy treatment, and overall survival rates are poor. Thus, UBC remains a challenge in the oncology fi eld, representing an ideal candidate for research on biomarkers that could identify patients at increased risk of recurrence, progression, and chemo-refractoriness. However, progress toward personalized medicine has been hampered by the unique genetic complexity of UBC. Recent genome-wide expression and sequencing studies have brought new insights into its molecular features, pathogenesis and clinical diversity, revealing a landscape where classical pathology is intersected by the novel and heterogeneous molecular groups. Hence, it seems plausible to postulate that only an integrated signature of prognostic/predictive biomarkers inherent in different cancer hallmarks will reach clinical validation. In this review, we have summarized ours and others' research into novel putative biomarkers of progression and chemoresistance that encompass several hallmarks of cancer: tumor neovascularization, invasion and metastasis, and energy metabolism reprogramming of the tumor microenvironment.
Introduction
The urothelium, one of the slowest cycling epithelia in the human body, [1] is constantly exposed to a variety of potential carcinogens that can stagnate in urine for a few hours before urination. For that reason, the bladder is a particularly high-risk organ for cancer development, and incidence and mortality from bladder cancer represent an important public health problem. An estimated 429,000 new cases of bladder cancer and 165,000 deaths occurred in 2012, worldwide. It was the 9th most common cancer for both sexes combined (4th in men, 15th in women). Sixty percent of cases occurred in more developed regions of the world (Europe, North America, North Africa). [2] In these regions, more than 90% of all bladder tumors originate from transitional cells of the urothelium, while approximately 5% and 2% are squamous and glandular variants, respectively, while the remainder comprises other rare subtypes. [3, 4] The most well-established risk factors for bladder carcinogenesis are cigarette smoking and industrial exposures in the context of a number of occupational settings. [5] Of all newly diagnosed cases of urothelial bladder carcinoma (UBC), 70-80% arise as non-muscle invasive (NMI). These tumors, although without aggressive histopathological features, often experience recurrence, and a subgroup of high-risk lesions frequently progress to invasive forms. Conversely, 20-30% originally present as muscle invasive (MI) disease. Invasion of the muscular wall portends common progression to metastasis. Despite radical cystectomy, radiation, and/or platinum-based chemotherapy, patients often fail treatment, so the 5-year overall survival (OS) rate is < 50%, mostly due to chemotherapy resistance and patient fragility. [4, [6] [7] [8] [9] Repeated relapses, occurrence of progression, and chemoresistance make UBC the costliest cancer to treat from diagnosis to death. [10] Thus, personalization of treatment could improve patients' quality of life, and reduce the burden on health care systems.
Clinical staging and histopathological parameters remain the "gold standards" for UBC diagnosis and prognostic prediction. [11, 12] However, they are not suffi cient to characterize individual biological features and clinical tumor behavior. Understanding disease pathobiology could potentially add essential information to these classical criteria and contribute to more accurately predicting prognosis and refi ne treatment. Ideally, the clinical use of standardized prognostic and predictive biomarkers could allow the prediction of tumor recurrence through a non-invasive method, avoiding use of invasive techniques, such as cystoscopy and biopsy, which cause signifi cant patient discomfort and add substantial costs. [13] Furthermore, it could allow timely prediction of UBC progression, from NMI to MI disease, particularly for high grade or carcinoma in situ lesions, guiding more vigilant surveillance and refi ning treatment strategies. [14] Finally, it could allow the prediction of response to conventional cytotoxic therapies typically associated with chemorefractory relapse and patient fragility. [15] A cancer-related biomarker may be defi ned as a molecule produced by the tumor or by the organism in response to the tumor, measurable in sample matrices such as tissue, blood, or urine, representative of the cancerous process, and reproducible, specifi c, and sensitive. [16] A reasonable number of UBC biomarkers, namely those involved in the key molecular pathways of urothelial malignization (fi broblast growth factor receptor 3 and tumor protein p53 mutations), seem to be prognostically relevant. [17] [18] [19] Despite this, there is a substantial delay in translation into the clinic, and clinical trials with molecularly targeted agents have been few in number and largely unsuccessful. [20] There is the need to expand biomarker research beyond the current focus on therapies directed at deregulated oncogenic or tumor suppressor pathways, and into new molecular portraits encompassing all the hallmarks of cancer. [21] In fact, recent medium-to high-throughput gene expression profi ling technologies and sequencing studies have revealed a multifactorial scenario where additional molecular alterations seem to be involved in urothelial carcinogenesis and tumor progression. [8] 
Biomarkers of UBC Progression: Lessons Learned from the Bench
In the next sections, we will summarize the contributions of our group and of other authors to the research of three poorly explored biological events that overlap several cancer hallmarks and seem to infl uence UBC progression: occurrence of tumor neovascularization, loss of metastasis suppressor proteins, and metabolic reprogramming of the tumor microenvironment.
Tumor neovascularization
The leading cause of mortality from cancer is not the primary tumor itself, but the occurrence of metastasis from the primary tumor. [22, 23] Disease dissemination can occur by direct invasion of tissues and cavities surrounding the primary site. However, the preferential course for metastases is spread through blood or lymphatic vasculature. Moreover, several preclinical and clinical studies have highlighted the preponderance of the lymphatic vascular system over the blood vascular system with the involvement of the sentinel lymph node being a standard diagnostic and prognostic parameter. [24, 25] The occurrence of "de novo" vascularization is a crucial step in the metastatic route. In fact, the tumor neovasculature not only supports the metabolic needs of the malignant cells, but also establishes the routes for dissemination. The malignant cells overexpress various angiogenic and lymphangiogenic growth factors that alter the normal neovascularization pattern, signifi cantly increasing blood and lymphatic vessel density ( BVD and LVD, respectively). [26] The link between neovascularization and lymphovascular invasion signifi cantly worsens prognosis, with numerous reports on its association with risk of tumor recurrence, progression, lymph node metastasis, and distant metastasis. [27, 28] Accordingly, several preclinical models have demonstrated a signifi cant reduction in tumor growth and tumor associated-neovasculature when the expression of angiogenic and lymphangiogenic factors was blocked. [29] [30] [31] Anti-angiogenic/lymphangiogenic agents and targeted inhibitors, in monotherapy or in combination with standard chemotherapeutic drugs, have already reached the phase of clinical trials, and several compounds have obtained approval from the Food and Drug Administration agency. [32, 33] While these agents have shown promising therapeutic effects, substantial evidence of primary and acquired resistance has been reported. [34] Vessel normalization, by restoring physiological perfusion and oxygenation of tumor vasculature, has recently emerged as a promising strategy to overcome resistance to certain antiangiogenic therapies. [35] In the setting of UBC, angiogenesis has been extensively reported, with several studies, including large-scale approaches, indicating the independent prognostic value of high vascular endothelial growth factor (VEGF) levels and BVD counts. [36] [37] [38] [39] [40] A number of clinical trials with anti-angiogenic agents are ongoing for UBC patients with NMI and MI disease. [41] Reports on lymphangiogenesis, although fewer in number, also point to a signifi cant role of lymphatic vessel formation in UBC spread. Overexpression of VEGF-C, VEGF-D, and VEGFR-3, the key players of lymphangiogenesis, has been demonstrated in several studies, associating with high LVD counts and lymph node metastasis, also predicting poor prognosis. [40, [42] [43] [44] [45] In vitro and in vivo studies have shown that VEGF-C/D blockade suppresses lymphangiogenesis and lymphatic metastasis, enhancing UBC chemosensitivity. [46, 47] Therefore, there is no doubt that both blood and lymphatic vessels participate in the metastatic process. Lymphovascular invasion (LI) has been identifi ed as an independent prognostic factor for recurrence and OS. [48, 49] A recent meta-analysis demonstrated that LI is an important selection criterion for early cystectomy in high-grade stage T1 UBC. [50] Also demonstrated is that the LI status helps to stratify N0 UBC patients at increased risk of UBC recurrence and death. [51] Regardless of these important associations, LI occurrence is not included as a standard parameter in many pathology reports, mostly due to the lack of strict diagnostic criteria. [52, 53] In our research, in 83 UBC tissue sections, we used immunohistochemistry (IHC) (CD31 and D2-40 antibodies) to assess BVD and blood vessel invasion (BVI), and lymphatic vessel invasion (LVI), respectively [ Table 1 ]. [54] Regarding angiogenesis occurrence, although we observed an association between BVD and parameters of UBC aggressiveness and progression, we did not fi nd a signifi cant infl uence on prognosis. In fact, confl icting results exist, [38, 55, 56] and it has been advocated that additional factors are necessary to determine the real impact of angiogenesis in UBC progression and dissemination. [57] In accordance, BVI occurred more frequently in cases with high BVD and was identifi ed as an independent prognostic factor for OS. The same correlation was observed between LVD and LVI, although LVI was identifi ed as a prognostic factor only by univariate analysis. Nevertheless, high LVD was signifi cantly associated with tumor aggressiveness. These results have been corroborated by others. [58, 59] Moreover, we observed that intratumoral lymphatic vessels seemed to cooperate actively in malignant dissemination by the presence of single-malignant cells in well-preserved vessels [ Figure 1b ]. Although these vessels have been described as collapsed and non-functional by others, [60, 61] in our series, there was a signifi cant proportion of cases where vessels with visible lumina were seen; edema was not observed, which would support a more effi cient lymphatic fl ow. Accordingly, the presence of intratumoral lymphatic vessels was correlated with parameters of UBC aggressiveness in one study, [62] and was identifi ed as a predictive factor of pelvic lymph node metastasis in another. [59] Another result of our study was the validation of the use of IHC markers to separate blood and lymphatic vessels. Its usefulness was particularly important in the detection of isolated malignant cells invading lymphatic capillaries [ Figure 1b ]. These cells, intravased in a milieu that fl ows slowly and has a composition similar to interstitial fl uid, have a higher survival probability when compared to the typical rigors of the blood. [63] LVI by isolated malignant cells was signifi cantly correlated with a poor prognosis. The same association was observed when considering BVI, but only when malignant emboli were intravased [ Figure 1a ]. Thus, these parameters represent potential biomarkers of progression that can guide therapeutic regimes, and their routine evaluation is recommended by us and others. [53, 54] We additionally suggest specifi c immunostaining of blood and lymphatic vessels in histologically equivocal cases that require confi rmation in order to better identify lymphovascular invasion that could have been missed during routine evaluation on HE-stained tumor sections, and to allow a more accurate discrimination between the 2 forms of lymphovascular invasion.
As above, the occurrence of angiogenesis and lymphangiogenesis as potential targets for therapeutic intervention in UBC is already under clinical testing, with several compounds targeting the most relevant neovascularization signaling pathways. [41, 64] However, as with other types of cancer, the risk of refractoriness to VEGFs/VEGFRs signaling abrogation exists. [65] Compensatory mechanisms to VEGF blockade in UBC cell lines have been described. [66] While these anti-neovascularization compounds have clear value, additional efforts are being undertaken in the search of alternative pathways to abrogate angiogenesis/lymphangiogenesis. The mammalian target of the rapamycin (mTOR) intracellular pathway is an important signaling mediator in hypoxia-induced angiogenesis, [67] besides transducing activator signals for promoting cell growth. [68] UBC pre-clinical [69] and clinical trials, [70, 71] although few in number, [72] have shown the anti-angiogenic effects of rapamycin analogues. Nevertheless, levels of mTOR activation in UBC tissue sections have been little explored, with controversial results being found. [73, 74] We assessed phospho-mTOR (p-mTOR) levels in a series of 76 UBC tissue sections, where blood and lymphatic vessels were also specifi cally stained, in order to correlate angiogenesis and lymphangiogenesis with p-mTOR expression [ Table 1 ]. Representative tumor and non-tumor (normal-like or hyperplasic) areas were present. [75] We did not fi nd signifi cant associations between clinicopathological parameters, vascular density, and p-mTOR expression. Nonetheless, p-mTOR expression [ Figure 1c ] decreased with increasing stage and was lost from non-tumor to tumor urothelium, particularly in muscle-invasive tumors, where immunoexpression was only observed in cell clusters. Angiogenesis was compromised in T3/T4-negative cases; conversely, the group with T3/T4-positive tumors had a quite poor outcome, as observed by others. [73] These two patterns of expression, complete absence or presence in clusters of cells, are a possible consequence of opposing biological settings mediated by mTOR signalling. There is the need to expand the research on larger and comprehensive series of UBC patients, with molecular effectors of upstream and downstream mTOR signaling, together with reproducible IHC and molecular methodologies, and with in vivo and in vitro UBC models. This is in order to elucidate the role of the mTOR pathway in human UBC and to fi nd more appropriate target therapeutic strategies. Accordingly, recent studies characterizing UBC genetic background revealed chromosomal alterations not seen at the same level in other types of cancers, namely, mutations of genes involved in the PI3K/AKT/mTOR signaling pathway. [76] 
Tumor metastasis
The ability of malignant cells to leave a primary tumor and to disseminate widely is commonly agreed to be the basis for metastasis formation, the mainly cause of death from cancer. As above, angiogenesis and lymphangiogenesis are integrate parts of the metastatic process, but additional steps need to occur in order for a malignant cell or a cluster of cells colonize secondary sites. These interrelated steps involve the expression of molecular promoters and suppressors of metastasis. Moreover, the success of metastatic spread depends, not only on the intrinsic properties of the tumor cells, but also on host feedback. [77] Genes inhibiting metastasis without blocking the ability of the transformed cells to develop a primary tumor are included in the group of metastasis suppressors. Obviously, loss of expression of metastasis suppressor genes is part of the metastatic genetic program, and a mandatory requisite for the success of the process. After initial scepticism following the discovery of the Nm23 gene, more than thirty protein coding/non-coding genes have been described that signifi cantly reduce the onset of metastasis without affecting the formation of the primary tumor. Therefore, their loss occurs during cancer progression, not during transformation. [78, 79] In the UBC setting, progression of high-risk NMI tumors (high grade Ta/T1 tumors or carcinoma in situ) to muscle-invasive disease and ultimately, to extra-vesical dissemination, carries a signifi cant risk of invasion and metastasis, despite radical surgical treatment. [4] Inhibiting biomarkers of progression and metastasis represents an attractive therapeutic approach, but restoring the function of metastasis suppressor proteins, although poorly explored, is also appealing. In this picture, the role of the metastasis suppressor Raf kinase inhibitor protein ( RKIP) in cancer has been highlighted due to its ability to modulate several intracellular signaling pathways involved in cell differentiation, cell cycle kinetics, apoptosis, epithelial to mesenchymal transition, and cell migration. [80, 81] Given its pleiotropic abilities in maintaining cellular equilibrium, RKIP downregulation is associated with metastatic events in an increasing number of solid tumors. [82, 83] Its preponderance in UBC is largely unknown. In one study, [84] low mRNA levels were reported in NMI tumors when compared with normal urothelium. In our research, and for the fi rst time (to the best of our knowledge), we studied 81 tumor sections from UBC patients for RKIP immunostaining [ Table 1 ]. [85] We observed tumors with a favorable clinicopathological profi le, namely, NMI tumors where LVI was absent, with a homogeneous expression of RKIP. Conversely, LVI occurrence was associated with a heterogeneous pattern of RKIP expression, where expression intensity was lost from tumor center to invasion front [ Figure 1d ]. Low RKIP expression signifi cantly impacted prognosis, remaining an independent prognostic factor for disease-free survival. As mentioned, similar associations concerning other aggressive cancer types have been previously reported. Clinically, a gradual decrease of RKIP expression was noted from benign to malignant tumors, and from those to metastastic sites. [82, 83] In the UBC setting, additional studies are needed in order to confi rm our results and to expand research into therapeutic strategies that can potentially restore RKIP functionality. Besides acting as a biomarker of progression to metastatic disease, the potential role of RKIP as a predictive biomarker has also been proposed, since its expression may mediate apoptosis induced by chemotherapeutic regimes. [86, 87] 
Tumor metabolic reprogramming
Cancer is not only a complex genetic disease, but also a disease of deregulated bioenergetic metabolism. Elevated glycolytic rates are a common trait of malignancy. [88] Warburg was the fi rst to describe the metabolic switch, known as "The Warburg Effect," whereby a tumor cell avidly consumes glucose and reprograms its metabolism, producing large amounts of lactate, even under aerobic conditions. [89] Lactate is the main source of microenvironmental acidosis in tumors, contributing to an acid-resistant phenotype that supports increased migration and invasion abilities of cancer cells. [90] [91] [92] Its dependence on monocarboxylate transporters (MCTs) for transport across the plasma membrane directly implicates MCTs in tumor behavior.
Monocarboxylate transporters belong to the SLC16 gene family, comprising 14 members, of which MCTs 1-4, the proton-linked MCTs, mediate infl ux/effl ux of monocarboxylates across the plasma membrane. MCT1 and MCT4 are the best characterized MCTs in human tissue, with MCT1 having ubiquitous distribution and MCT4 being present in highly glycolytic tissues. [93] The proper expression of MCTs at the plasma membrane depends on their interaction with CD147, [94] a cell surface glycoprotein implicated in extracellular matrix remodeling, angiogenesis, migration, and invasion and related to chemoresistance-promoting events. [95] CD147 and MCTs overexpressions have been described in several cancers, associated with poor clinicopathological and survival parameters. [95, 96] Some in vitro models have demonstrated that CD147 downregulation sensitizes malignant cells to platinum-based therapy. [97] [98] [99] Therefore, metabolism-related cellular pathways involved in malignancy represent potential areas of therapeutic intervention.
Biological mechanisms that reprogram cellular energetics in the setting of UBC are poorly characterized. Thus, we investigated, in a series of tumor tissue sections from 114 UBC patients, a panel of three metabolism-involved molecules [ Table 1 ]. [100] The central protein seemed to be CD147. We had previously demonstrated the prognostic impact of its overexpression in UBC when we developed a model of UBC aggressiveness (n = 77) that included classical clinicopathological (stage and grade) and biological parameters (lymphovascular invasion [54] and CD147 expression). [101] In fact, this scoring system separated a low aggressive from the high aggressive group, remaining as an independent prognostic factor for disease-free and OS. In the group of highly aggressive tumors, CD147 positivity was 87%, clearly adding prognostic information to the model [ Table 1 ]. Thus, we decided to re-evaluate this glycoprotein in a larger series, exploring its crosstalk with MCTs and possible role in chemoresistance. [100] Signifi cant associations were found among the biomarkers, which support the chaperone function of CD147, as corroborated by others. [94] We also observed that CD147, MCT1, and MCT4 were upregulated [ Figure 1e -g], being signifi cantly associated with a poor clinicopathological profi le, namely, advancing stage, grade, type of lesion, and occurrence of LVI. Moreover, MCT1 and CD147 overexpressions were associated with poor prognosis, particularly in cases that were positive for both biomarkers. Interestingly, when we selected patients who received platinum-based chemotherapy, the prognosis was signifi cantly worse for those with MCT1-and CD147-positive tumors. Probably, MCT1 cooperates with CD147 in the promotion of a chemoresistance phenotype and possibly, of other functions primarily attributed to CD147. In fact, it appears that CD147 maturation is affected by MCT expression. [102] Other authors have identifi ed CD147 expression in UBC as an independent prognostic biomarker, [103, 104] and have additionally proposed it as a predictive biomarker in the setting of cisplatin-containing regimens. [104, 105] Recently, one group [106] demonstrated the independent prognostic signifi cance of MCT1 and MCT4 in UBC. Those results led us to knock down CD147 expression in a UBC cell line with a cisplatin-resistant phenotype. We found that CD147 depletion was accompanied by a decrease in MCT1 and MCT4 expressions, additionally supporting its chaperone function. Notably, we also found an increase in chemosensitivity to cisplatin. To the best of our knowledge, this is the fi rst study to assess MCT expression and correlation with CD147 in UBC tissue from platinum-treated patients, and to characterize UBC chemosensitivity to cisplatin in vitro upon CD147 inhibition. Our fi ndings reveal a major role of CD147 and companions in promoting progression of a UBC-aggressive phenotype, with high glycolytic activity, contributing to microenvironmental acidifi cation. This enables the malignant cell to demonstrate growth, migration, invasion, and chemoresistance abilities that can potentially be bypassed if new approaches of targeted therapeutic intervention are investigated. Though investigation of CD147 and its association with metabolic remodeling and chemoresistance is still in a preliminary phase in UBCs, progress has been made in other areas, and CD147-directed monoclonal antibodies have reached the phase of pre-clinical/clinical trials, namely for hepatocellular carcinoma. [107] 
Concluding Remarks
Urothelial bladder carcinoma represents about 90% of all cases of bladder cancer. [5] Its relapsing and progressive nature, and the disparities in treatment responses, are the major concerns in patient care and have a signifi cant socio-economic impact. [10] In an attempt to clarify its heterogeneous natural history and clinical behavior, recent progress has been made in genomic studies. [8, 108] This should help in refi ning our understanding of the pathogenesis of the disease and of the biological basis for outcome disparities. Furthermore, the consequent emergence of UBC biomarkers will allow us to identify patients at increased risk of recurrence, progression, metastasis, and/or chemorefractoryness, informing us about more effi cient treatment and surveillance strategies. In addition, biomarkers may improve prediction of response to treatment and guide us to an era of personalized medicine and targeted therapy. In fact, classical diagnostic and prognostic instruments, such as risk stratifi cation tables, [109, 110] nomograms, [111, 112] and artifi cial neural networks, [113, 114] would undoubtedly refi ne diagnosis, prognosis, and therapeutic decisions with the inclusion of prognostic and predictive biomarkers. Several studies have demonstrated the potential impact of developing risk stratifi cation tools that combine clinicopathological and biological parameters. [101, 115, 116] Moreover, it seems that integrating a molecular signature of biomarkers inherent in different cancer hallmarks improves predictive accuracy over one biomarker abnormality, as several biomarkers may help to elucidate individual biological features of tumors. [14, 101, [117] [118] [119] [120] Our previous study on a tumor aggressiveness scoring model, where we combined analysis of 2 clinicopathological parameters, stage and grade, with 3 biological parameters, BVI, LVI, and CD147 overexpression, also corroborates those premises [ Table 1 ]. [101] In fact, the recent genomic profi le of UBC revealed a more complex picture than it was previously supposed, with multiple molecular subclasses that traverse conventional grade and stage groupings. [76, 121, 122] This leads us to believe that only an integrated clinicopathological and molecular signature will refi ne prognostication and therapeutic index for UBC patients. Therefore, it is important to transpose tests on small groups of patients to large-scale independent validation assays, involving multiple institutions so that prospective validations and randomized trials based on the retrospective outcomes may then proceed. As stated, [123] any newly proposed anticancer strategy must integrate a personalized treatment outcome approach, ideally resulting in a predictive cancer staging system orientated toward the patient and the tumor, and a response evaluation system with multiple standardized variables.
